# NCT02716038 (NCT02716038)

> Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02716038
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Columbia University
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: MPDL3280A; Carboplatin; Nab-paclitaxel
- Enrollment: 39
- Primary outcome: Number of Subjects With Major Pathologic Response (MPR)

## Indexed commentary on NCT02716038 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02716038